-The use of a monoclonal antibody that reduced circulating IgG levels, led to a decrease in preexisting neutralizing antibodies (NAbs) to adeno-associated virus (AAV). The study, which showed that this strategy enabled gene delivery to the liver and heart via systemic AAV-based gene therapy in mice and non-human primates, is published in the peer-reviewed journal Human Gene Therapy. Click here to read the article now.
AAV vectors represent the leading platform for gene delivery to treat rare genetic disorders. However, the prevalence of natural humoral immunity, with Nabs, prevents a significant proportion of the population from being treated with AAV-based gene therapy. IgG appears to be the predominant antibody class among Nabs. Inhibitors of the neonatal Fc receptor (FcRn) represent one group of IgG-reducing drugs in clinical development. M281 is a anti-human FcRn monoclonal antibody that can reduce IgG levels to less than 20% of the baseline level.
In the current study, James M. Wilson, MD, PhD, from the Perelman School of Medicine, University of Pennsylvania, and coauthors, evaluated the effect of M281-mediated IgG reduction on pre-existing NAb titers and gene transduction in the context of systemic AAV-based gene therapy in mice and non-human primates.
Based on their results, the investigators concluded that “mitigating pre-existing humoral immunity via disruption of the neonatal Fc receptor-IgG interaction may make adeno-associated virus-based gene therapies effective in neutralizing antibody-positive patients.”
“The presence of neutralizing antibodies to AAV can disqualify some patients from receiving gene therapy,” says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Chan Medical School. “This intervention has the potential to circumvent that limitation and allow more patients to benefit from gene therapy in the future.”
About the Journal
Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy and eight other international gene therapy societies, was the first peer-reviewed journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. The Journal is led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Chan Medical School, and an esteemed international editorial board. Human Gene Therapy is available in print and online. Complete tables of contents and a sample issue are available on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.